oral glp 1 Novo Nordisk's GLP-1 drug didn't work on Alzheimer's as hoped, but don't call it a failure US FDA accepts Novo Nordisk's

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a novel and effective solution, having initially been approved and marketed for glycemic control in type 2 diabetes

The trade-off is the inconvenience of more frequent injections and potentially faster use of supplies

The effects of GLP-1RAs on prostate cancer risk Preclinical studies have demonstrated that GLP-1RAs are capable of inhibiting the proliferation of prostate cancer cells in both in vivo and in vitro experiments, thereby suggesting potential preventative effects [36]

Burns says he asks every new patient with type 2 diabetes: "Has anyone ever told you this is reversible?" He says, Invariably, they say no. But type 2 diabetes can be reversed through diet

Over half of users said their GLP-1s were difficult to afford, and many who had stopped the treatment cited the cost

doi: 10.2215/CJN.11491116